Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Pharmaceuticals Monthly Deals Analysis - Partnerships, Licensing, Investments and M&A Trends

Enquire | Email | Print

ISBN: GDPH0430MD
Published Date: Nov, 2013
Format: PDF
No of Pages: 107
 
 
Select pricing :
Change Currency: EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Summary

“Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last five quarters.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of company divesting and acquiring assets and ways to raise capital in the market.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the oil and gas industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2013 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
2.2.1 McKesson to Acquire Celesio for US$8.3 Billion 14
2.2.2 Bristol-Myers Squibb Completes Public Offering of Notes for US$1.5 Billion 16
2.2.3 Ventas Acquires Portfolio of Independent Living Communities from Holiday Retirement for US$790 Million 16
2.2.4 BioMarin Pharma Completes Public Offering of Notes for US$750 Million 16
2.2.5 Astellas Pharma Enters Into R&D Agreement with Mitokyne for Drug Discovery 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2013 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2013 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2013 20
3.1.1 Top M&A Deals in October 2013 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2013 - October 2013 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2013 23
3.2.1 Top Equity Offering Deals in October 2013 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2013 - October 2013 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2013 27
3.3.1 Top PE/VC Deals in October 2013 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2013 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2013 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2013-October 2013 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013-October 2013 34
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2013 - October 2013 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 39
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2013 41
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2013 - October 2013 44
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 45
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 51
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2013 53
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2013 53
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2013 54
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2013 - October 2013 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2013 - October 2013 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 61
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2013 63
6.1.1 Oncology - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2013 67
6.2.1 Central Nervous System - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2013 70
6.3.1 Immunology - Dealsof the Month 72
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2013 73
6.4.1 Infectious Diseases - Deals of the Month 75
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, October 2013 76
6.5.1 Metabolic Disorders - Deal of the Month 78
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2013 81
6.6.1 Cardiovascular - Deal of the Month 82
6.7 Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals, October 2013 84
6.7.1 Hematological Disorders - Deal of the Month 85
7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2013 87
7.1.1 North America - Deals of the Month 89
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2013 91
7.2.1 Europe - Deals of the Month 92
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2013 94
7.3.1 Asia-Pacific - Deals of the Month 96
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2013 97
7.4.1 Rest of the World - Deals of the Month 99
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 100
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2013 - October 2013 100
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2013 - October 2013 102
9 Further Information 104
9.1 Methodology 104
9.2 About GlobalData 105
9.3 Disclosure information 106
9.4 Disclaimer 106

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2013 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2013 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2013 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2013 - October 2013 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2013 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013 - October 2013 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 40
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 41
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 43
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2013 - October 2013 48
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 50
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 52
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2013 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2013 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 56
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2013 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 62
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 64
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 71
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 74
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 77
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 82
Table 38: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 85
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 95
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 98
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 101
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 103

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2013 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2013 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 45
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 49
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 51
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2013 - October 2013 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 60
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 61
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 63
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 67
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 70
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 73
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 76
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 81
Figure 33: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 84
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 94
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 100
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 102

Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 438192, price: INR 60904, GlobalData

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online